Garrett's retatrutide side effects warning, fact-checked

What does this video actually claim?

@garrettwayne0 warns viewers about "scary side effects" of retatrutide, positioning himself as someone sharing important safety information about this experimental peptide. The video appears to focus on potential adverse effects without much context about the drug's development status or clinical data.

Garrett presents these warnings as if retatrutide is widely available, but he's talking about a drug that's still in Phase 3 trials. This framing matters because it suggests people are commonly using something that's actually only available through clinical studies or gray-market peptide suppliers.

What do the clinical trials actually show about side effects?

The Phase 2 trial (Rosenstock et al., NEJM, 2023) gives us real data on retatrutide's side effects in 338 participants over 48 weeks. Gastrointestinal issues dominated: nausea hit 60-80% of patients depending on dose, vomiting affected 24-48%, and diarrhea occurred in 46-76%.

These rates are actually higher than what we see with semaglutide or tirzepatide. The 12mg dose was particularly brutal, with treatment discontinuation rates around 15% primarily due to GI intolerance.

More concerning were the injection site reactions, which affected up to 67% of participants at higher doses. That's unusually high for GLP-1 class drugs and suggests formulation issues that Eli Lilly is still working through.

What's misleading about focusing on retatrutide side effects right now?

Garrett's treating retatrutide like it's a available medication people are choosing between, but it's not. You can't get legitimate retatrutide outside of clinical trials. The drug won't hit the market until 2026 at earliest, assuming Phase 3 trials succeed.

Anyone claiming to sell retatrutide online is either lying or selling unregulated research chemicals. The "side effects" people experience from these products could be from anything since there's no quality control or standardized dosing.

Warning about side effects of an unavailable drug while ignoring that availability issue is like reviewing the safety of flying cars. Technically accurate information presented in a misleading context.

How does retatrutide actually compare to existing options?

The Phase 2 data showed 17.5% weight loss at 48 weeks with the 12mg dose, compared to 2.4% with placebo. That's impressive but came with those high side effect rates we mentioned.

For comparison, tirzepatide achieved 22.5% weight loss in its Phase 3 SURMOUNT-1 trial with more tolerable side effects. Semaglutide 2.4mg hit 14.9% weight loss in STEP 1 with even better tolerability.

So retatrutide might offer benefits over current options, but the risk-benefit profile isn't clearly superior. Eli Lilly is reformulating to improve tolerability for Phase 3, which tells you everything about how the current version performed.

What should you actually know about retatrutide?

If you're interested in retatrutide, your only legitimate option is enrolling in clinical trials. Eli Lilly is recruiting for Phase 3 studies that will run through 2025-2026.

The drug targets GLP-1, GIP, and glucagon receptors simultaneously, which explains both the impressive weight loss and the harsh side effects. More targets often means more effects, both wanted and unwanted.

Anyone selling retatrutide peptides online is operating in an unregulated space where you have no idea what you're actually getting. The side effects from those products could be completely different from what clinical trials show because you're not getting the same drug.